|
PresView™ and Glaucoma
Refocus Group's Mission is to Become a Surgical Standard of Care for Primary Open-Angle Glaucoma and Ocular Hypertension Worldwide
Note: The company’s primary product, the PresVIEW™ Scleral Implant, is an investigational device and is not yet approved for sale or use in the United States or Canada. However, the product is currently approved for sale in the European Union.
Limited clinical trials of SSP for the management of Ocular Hypertension and Glaucoma have taken place in Canada, and the company is currently supporting an ongoing clinical study in Germany.
|
 |
| Patients Click This Image! |
|
|
 |
| Professionals Click This Image! |
|
|
|
